• Why this health tech group picked Nashville – not Silicon Valley — to help unlock the future of health care
    anemptytextlline
  • Distress Index: The third quarter 2014 results for the FBT/TrBK Distress Indices have just been released.
    anemptytextlline
  • Distress to Success: A Survival Handbook For Struggling Businesses and Buyers of distressed Opportunities
    anemptytextlline
  • Give your business the mirror test - is your company really breathing?
    anemptytextlline
  • Attacks Continue on Lenders’ Right to Credit Bid in 363 sales
    anemptytextlline
  • Antitrust Concerns May Block Section 363 Sales
    anemptytextlline
  • THE GREATEST THREAT TO R&D COMPANIES : A LOSS IN THE LAB
    anemptytextlline
  • INSURANCE & RISK MANAGEMENT: For Global Human Clinical Trials
    anemptytextlline
  • Three Bets At The Table: The Major Distressed Investing Strategies For Hedge Funds and Private Equity
    anemptytextlline
  • HOW PRO’S PLAY LOAN-TO-OWN GAME
    anemptytextlline
  • Hot Opportunities in a Cooling Economy: Buying Struggling Facilities at Distress Sales
    anemptytextlline
  • Why Up-Market, Down-Market Acquisitions are different
    anemptytextlline

INSURANCE & RISK MANAGEMENT: For Global Human Clinical Trials

INSURANCE & RISK MANAGEMENT: For Global Human Clinical Trials

April 8, 2011: By Daniel Brettler, Senior Vice President, Conner Strong

Often overlooked in the early planning of a human clinical trial, insurance requirements specific to foreign jurisdictions may have a significant impact on a company’s clinical program and a material impact on its bottom line. The clinical impact may include delay in enrollment as well as a decision not to enroll at all in a particular country from a cost/benefit perspective. Historically, the costs to secure insurance meeting local requirements were insignificant and therefore typically not strategic to the clinical trials planning process. An evolution has taken place in recent years outside of the United States whereby a more uniform approach to protecting patients in human clinical trials has prevailed and continues to gain momentum in just about every country today. This movement towards uniform protection has created a complexity of risk management and insurance issues for both insurance company and life science company alike.   Read more